<DOC>
	<DOC>NCT01332344</DOC>
	<brief_summary>The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg ("FSC 100/50") or inhaled corticosteriods in typical clinical practice using a retrospective observational cohort study design of large managed care database.</brief_summary>
	<brief_title>Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Subjects with asthma as determined by ICD9 codes and asthma drug use at least 12 years of age treated with inhaled corticosteroids Subjects with COPD or treatment for COPD</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>fluticasone propionate/salmeterol combination</keyword>
	<keyword>Asthma</keyword>
	<keyword>inhaled corticosteroids</keyword>
	<keyword>outcomes</keyword>
</DOC>